Official Title
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation
Brief Summary

The primary endpoint of this study is to assess the effects of a single IV dose of mavrilimumab on the acute inflammatory response in patients with severe COVID-19 pneumonia

Status
Not yet recruiting
Conditions
COVID-19
Interventions

Drug: Mavrilimumab
single IV dose of mavrilimumab
Mavrilimumab

Eligibility Criteria

Inclusion Criteria:

- Documented COVID19 pneumonia (positive SARS-CoV2 test, bilateral abnormalities/ infiltrates on chest x-ray or computed tomography, active fever or documented fever within 24-48 or ongoing anti-pyretic use to suppress fever).

- Hypoxia (room air SpO2 5 mg/dl AND LDH >upper limit of normal for local laboratory).

Exclusion Criteria:

- Onset of COVID-19 >14 days

- Hospitalized >7 days

- Mechanically ventilated

- Age

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years
Countries
United States
Locations

Virginia Commonwealth University
Richmond, Virginia, 23298

Investigators

Antonio Abbate, MD, PhD
Principal Investigator
Virginia Commonwealth University

Sponsors / Collaborators
Virginia Commonwealth University
NCT Number
NCT04337216
MeSH Terms
Pneumonia
Respiratory Insufficiency
Inflammation
Mavrilimumab